Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

By Padmanabhan Ananthan (Reuters) -In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal in a late-stage trial for patients aged ...

Drugmaker Pfizer ($PFE) recently shared disappointing news about its experimental drug for sickle cell disease, inclacumab. In a late-stage ...

When Global Blood Therapeutics (GBT) IPO'd last August, shares priced above their expected range at $20 and skyrocketed at the open to $34.

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the presentation of a case study highlighting the effect of GBT440 ...

Shares of Global Blood Therapeutics Inc., based just outside San Francisco, rose more than 4% to $66.68 before the opening bell. Shares of Pfizer were essentially flat.

For Q1 2018 (ended on March 31), Global Blood Therapeutics posted $41.6M ($0.87 per share) net losses compared to $23.3M ($0.60 per share) declines (for the same period a year prior).

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq: GBT), a clinical-stage biopharmaceutical company determined to discover, develop and ...

* Global Blood Therapeutics Inc - ‍qtrly cash, cash equivalents, marketable securities $259.4 million at Sept 30, 2017 versus $197.3 million at Dec 31, 2016 Source text for Eikon: Further ...